Orchestra BioMed Holdings (OBIO) Profit After Tax Growth (1y) (2022 - 2026)

Orchestra BioMed Holdings (OBIO) Profit After Tax Growth (1y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -107.76%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 111.59%
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Orchestra BioMed Holdings 235.83 Mn 141.43 Mn 78,000.00 -10.32%

Historic Data

Download Data
DateValue
Mar 31, 2026 -10.32%
Dec 31, 2025 138.49%
Sep 30, 2025 -35.90%
Jun 30, 2025 -21.17%
Mar 31, 2025 -39.31%
Dec 31, 2024 -26.88%
Sep 30, 2024 -15.10%
Jun 30, 2024 -32.66%
Mar 31, 2024 -23.06%
Dec 31, 2023 -31.47%
Sep 30, 2023 -29.32%
Jun 30, 2023 -53.51%
Mar 31, 2023 -90.96%
Dec 31, 2022 -10,978.16%
Sep 30, 2022 -11,272.51%
Jun 30, 2022 -8,398.95%
Mar 31, 2022 -5,204.53%